---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Development and Commercialization of Metarrestin and Its Analogs for the Treatment of Metastatic Cancers"
date: 2026-02-05 18:36:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-06318
original_published: 2023-03-28 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Development and Commercialization of Metarrestin and Its Analogs for the Treatment of Metastatic Cancers

**Published:** February 05, 2026 18:36 UTC
**Source:** Federal Register
**Original Published:** March 28, 2023 00:00 UTC
**Document Number:** 2023-06318

## Summary

The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Oncala Bio Inc. ("Oncala Bio"), headquartered in Bend, OR.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/28/2023-06318/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-metarrestin)
- API: https://www.federalregister.gov/api/v1/documents/2023-06318

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
